These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

192 related articles for article (PubMed ID: 15561851)

  • 21. Role of the CmeABC efflux pump in the emergence of fluoroquinolone-resistant Campylobacter under selection pressure.
    Yan M; Sahin O; Lin J; Zhang Q
    J Antimicrob Chemother; 2006 Dec; 58(6):1154-9. PubMed ID: 17023497
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Development of resistance to ciprofloxacin, rifampin, and mupirocin in methicillin-susceptible and -resistant Staphylococcus aureus isolates.
    Schmitz FJ; Fluit AC; Hafner D; Beeck A; Perdikouli M; Boos M; Scheuring S; Verhoef J; Köhrer K; Von Eiff C
    Antimicrob Agents Chemother; 2000 Nov; 44(11):3229-31. PubMed ID: 11036061
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Searching for the Optimal Predictor of Ciprofloxacin Resistance in Klebsiella pneumoniae by Using In Vitro Dynamic Models.
    Strukova EN; Portnoy YA; Romanov AV; Edelstein MV; Zinner SH; Firsov AA
    Antimicrob Agents Chemother; 2015 Dec; 60(3):1208-15. PubMed ID: 26643328
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Effect of GrlA mutation on the development of quinolone resistance in Staphylococcus aureus in an in vitro pharmacokinetic model.
    Oonishi Y; Mitsuyama J; Yamaguchi K
    J Antimicrob Chemother; 2007 Nov; 60(5):1030-7. PubMed ID: 17827137
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Increased antibacterial activity of DW286, a novel fluoronaphthyridone antibiotic, against Staphylococcus aureus strains with defined mutations in DNA gyrase and topoisomerase IV.
    Yun HJ; Min YH; Jo YW; Shim MJ; Choi EC
    Int J Antimicrob Agents; 2005 Apr; 25(4):334-7. PubMed ID: 15784314
    [TBL] [Abstract][Full Text] [Related]  

  • 26. In vitro infection model characterizing the effect of efflux pump inhibition on prevention of resistance to levofloxacin and ciprofloxacin in Streptococcus pneumoniae.
    Louie A; Brown DL; Liu W; Kulawy RW; Deziel MR; Drusano GL
    Antimicrob Agents Chemother; 2007 Nov; 51(11):3988-4000. PubMed ID: 17846144
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Emergence of high-level fluoroquinolone resistance in emm6 Streptococcus pyogenes and in vitro resistance selection with ciprofloxacin, levofloxacin and moxifloxacin.
    Malhotra-Kumar S; Van Heirstraeten L; Lammens C; Chapelle S; Goossens H
    J Antimicrob Chemother; 2009 May; 63(5):886-94. PubMed ID: 19279051
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Rapid method for detection of gyrA and grlA mutations in unrelated strains of Staphylococci susceptible and resistant to levofloxacin.
    Messina C; Cafiso V; Campanile F; Santagati M; Stefani S
    New Microbiol; 2001 Oct; 24(4):347-53. PubMed ID: 11718372
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Dichotomous selection of high-level oxacillin resistance in Staphylococcus aureus by fluoroquinolones.
    Dalhoff A; Schubert S
    Int J Antimicrob Agents; 2010 Sep; 36(3):216-21. PubMed ID: 20630710
    [TBL] [Abstract][Full Text] [Related]  

  • 30. [Mutant prevention concentrations of fluoroquinolones for Staphylococcus aureus].
    Cui JC; Liu YN; Wang R; Liang BB; Pei F; Zheng ZJ
    Zhonghua Yi Xue Za Zhi; 2004 Nov; 84(22):1863-6. PubMed ID: 15631794
    [TBL] [Abstract][Full Text] [Related]  

  • 31. GyrA sequence analysis of Staphylococcus aureus and methicillin-resistant S. aureus strains selected, in vitro, for high-level ciprofloxacin resistance.
    Peterson LR; Willard KE; Sinn LM; Fasching CE; Gerding DN
    Diagn Microbiol Infect Dis; 1993; 17(2):97-101. PubMed ID: 7902228
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Testing the mutant selection window hypothesis with Staphylococcus aureus exposed to daptomycin and vancomycin in an in vitro dynamic model.
    Firsov AA; Smirnova MV; Lubenko IY; Vostrov SN; Portnoy YA; Zinner SH
    J Antimicrob Chemother; 2006 Dec; 58(6):1185-92. PubMed ID: 17028094
    [TBL] [Abstract][Full Text] [Related]  

  • 33. In vitro resistance studies with bacteria that exhibit low mutation frequencies: prediction of "antimutant" linezolid concentrations using a mixed inoculum containing both susceptible and resistant Staphylococcus aureus.
    Firsov AA; Golikova MV; Strukova EN; Portnoy YA; Romanov AV; Edelstein MV; Zinner SH
    Antimicrob Agents Chemother; 2015 Feb; 59(2):1014-9. PubMed ID: 25451050
    [TBL] [Abstract][Full Text] [Related]  

  • 34. [Investigation of the effect of efflux pump inhibitors to MIC values of ciprofloxacin in clinical isolates of Pseudomonas aeruginosa, Escherichia coli, Acinetobacter baumannii and Staphylococcus aureus].
    Cetinkaya E; Coban AY; Durupinar B
    Mikrobiyol Bul; 2008 Oct; 42(4):553-61. PubMed ID: 19149076
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Increased expression of fibronectin-binding proteins by fluoroquinolone-resistant Staphylococcus aureus exposed to subinhibitory levels of ciprofloxacin.
    Bisognano C; Vaudaux PE; Lew DP; Ng EY; Hooper DC
    Antimicrob Agents Chemother; 1997 May; 41(5):906-13. PubMed ID: 9145842
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Mechanisms and frequency of resistance to gatifloxacin in comparison to AM-1121 and ciprofloxacin in Staphylococcus aureus.
    Ince D; Hooper DC
    Antimicrob Agents Chemother; 2001 Oct; 45(10):2755-64. PubMed ID: 11557465
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Mutant prevention concentrations of ciprofloxacin and enrofloxacin for Salmonella enterica.
    Randall LP; Cooles SW; Piddock LJ; Woodward MJ
    J Antimicrob Chemother; 2004 Sep; 54(3):688-91. PubMed ID: 15243029
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Pharmacodynamics of levofloxacin against characterized ciprofloxacin-resistant Streptococcus pneumoniae.
    Lister PD
    Postgrad Med; 2008 Sep; 120(3 Suppl 1):46-52. PubMed ID: 18931471
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Pharmacodynamics of the antibacterial effect and emergence of resistance to tomopenem, formerly RO4908463/CS-023, in an in vitro pharmacokinetic model of Staphylococcus aureus infection.
    MacGowan AP; Bowker KE; Noel AR
    Antimicrob Agents Chemother; 2008 Apr; 52(4):1401-6. PubMed ID: 18227179
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Mutant prevention concentration of ozenoxacin for quinolone-susceptible or -resistant Staphylococcus aureus and Staphylococcus epidermidis.
    López Y; Tato M; Gargallo-Viola D; Cantón R; Vila J; Zsolt I
    PLoS One; 2019; 14(10):e0223326. PubMed ID: 31596898
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.